Renal Cell Carcinoma: Global Drug Forecast and Market Analysis to 2028
Summary
Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, making up 90-95% of all kidney cancer cases. Globally, RCC represents the sixth most frequently diagnosed cancer in men and 10th in women. RCC consists of a heterogeneous group of tumors with distinct genetic and metabolic defects. The major histologic RCC subtype is ccRCC, which represents 80-95% of cases (as shown in Table 2). Other forms of the disease, usually referred as non-clear cell RCC (nccRCC), include papillary RCC (PRCC), chromophobe RCC (ChRCC), translocation carcinoma, medullary carcinoma, and collecting duct carcinoma. At present, metastatic RCC (mRCC) is considered incurable, with only a small minority of patients achieving a complete response (CR) to treatment. However, major advances in the treatment landscape within the past 15 years have significantly improved progression-free survival (PFS) and overall survival (OS).
The publisher is expecting a total of 7 new entrants to launch over the forecast period in the 8MM from 2018-2028 while specific marketed agents are expected to undergo label expansion. The competition will be particularly fierce in renal cell carcinoma, immune checkpoint inhibitors and combinations thereof competing for market share in the adjuvant setting and in fist-line treatment of metastatic RCC. No drugs are currently in late development for nccRCC leaving the treatment of that population an unmet need within the forecast period.
KEY QUESTIONS ANSWERED
Scope
Reasons to Buy
The report will enable you to -
Summary
Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, making up 90-95% of all kidney cancer cases. Globally, RCC represents the sixth most frequently diagnosed cancer in men and 10th in women. RCC consists of a heterogeneous group of tumors with distinct genetic and metabolic defects. The major histologic RCC subtype is ccRCC, which represents 80-95% of cases (as shown in Table 2). Other forms of the disease, usually referred as non-clear cell RCC (nccRCC), include papillary RCC (PRCC), chromophobe RCC (ChRCC), translocation carcinoma, medullary carcinoma, and collecting duct carcinoma. At present, metastatic RCC (mRCC) is considered incurable, with only a small minority of patients achieving a complete response (CR) to treatment. However, major advances in the treatment landscape within the past 15 years have significantly improved progression-free survival (PFS) and overall survival (OS).
The publisher is expecting a total of 7 new entrants to launch over the forecast period in the 8MM from 2018-2028 while specific marketed agents are expected to undergo label expansion. The competition will be particularly fierce in renal cell carcinoma, immune checkpoint inhibitors and combinations thereof competing for market share in the adjuvant setting and in fist-line treatment of metastatic RCC. No drugs are currently in late development for nccRCC leaving the treatment of that population an unmet need within the forecast period.
KEY QUESTIONS ANSWERED
- Seven late-stage pipeline agents are going to enter the renal cell carcinoma market from 2018 onwards. What impact will these agents have on the market?
- Which of these drugs will have the highest peak sales, and why?
- What are the current unmet needs in renal cell carcinoma, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
- What is the market outlook in the 8MM from 2018-2028? Consideration of major patent expiries, launch of new premium priced agents and expected label expansions.
- What are the main corporate trends? Who are the current and future players?
Scope
- Overview of renal cell carcinoma including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline renal cell carcinoma market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting renal cell carcinoma therapeutics sales in the 8MM.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global renal cell carcinoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global renal cell carcinoma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global renal cell carcinoma market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the renal cell carcinoma therapeutics market from 2018-2028.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1 Table of Contents1.1 List of Tables
1.2 List of Figures
2 Renal Cell Carcinoma: Executive Summary
2.1 The RCC market is expected to grow to $6.4B in 2028
2.2 The Development of Combination Treatments Is the Pillar of Corporate Strategies in RCC
2.3 Opportunities Remain for More Effective Therapies and Treatments for nccRCC
2.4 The RCC Pipeline Is Diverse, Comprising Label Expansions and Novel Mechanisms of Action
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Prognostic models
4.3 Biomarkers
4.4 Clinical Staging
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods, Population
5.4.3 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC
5.4.4 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC by Stage at Diagnosis
5.4.5 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC by Prognostic Model
5.4.6 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC by Biomarkers
5.4.7 Forecast Assumptions and Methods, Five-Year and 10-Year Diagnosed Prevalent Cases of RCC
5.5 Epidemiological Forecast for RCC (2018-2028)
5.5.1 Diagnosed Incident Cases of RCC
5.5.2 Age-Specific Diagnosed Incident Cases of RCC
5.5.3 Sex-Specific Diagnosed Incident Cases of RCC
5.5.4 Diagnosed Incident Cases of RCC by Stage at Diagnosis
5.5.5 Diagnosed Incident Cases of RCC Stage IV by Prognostic Model
5.5.6 Diagnosed Incident Cases of RCC Stage IV by Biomarkers
5.5.7 Five-Year Diagnosed Prevalent Cases of RCC
5.5.8 10-Year Diagnosed Prevalent Cases of RCC
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis
6 Disease Management
7 Competitive Assessment
8 Unmet Needs and Opportunity Assessment
9 Pipeline Assessment
10 Current and Future Players
11 Market Outlook
12 Appendix
List of Tables
Table 1: RCC: Key Metrics in the 8MM
Table 2: Classifications of RCC
Table 3: TNM and Staging Classification System for RCC
Table 4: Risk Factors and Comorbidities for RCC
Table 5: RCC Clinical Stages at Diagnosis
Table 6: Treatment Guidelines for RCC
Table 7: Country Profile - US
Table 8: Country Profile - 5EU
Table 9: Country Profile - Japan
Table 10: Leading Treatments for Disease RCC, 2019
Table 11: Pfizer’s RCC Portfolio Assessment, 2019
Table 12: Merck & Co.’s RCC Portfolio Assessment, 2019
Table 13: BMS’s RCC Portfolio Assessment, 2019
Table 14: Exelixis’ RCC Portfolio Assessment, 2019
Table 15: Eisai’s RCC Portfolio Assessment, 2019
Table 16: RCC Market - Global Drivers and Barriers, 2018-2028
Table 17: Key Events Impacting Sales for RCC in the US, 2018-2028
Table 18: RCC Market - Drivers and Barriers in the US, 2018-2028
Table 19: Key Events Impacting Sales for RCC in the 5EU, 2018-2028
Table 20: RCC Market - Drivers and Barriers in the 5EU, 2018-2028
Table 21: Key Events Impacting Sales for RCC in Japan, 2018-2028
Table 22: RCC Market - Global Drivers and Barriers in Japan, 2018-2028
Table 23: Key Events Impacting Sales for RCC in China, 2018-2028
Table 24: RCC Market - Global Drivers and Barriers in China, 2018-2028
Table 25: Key Historical and Projected Launch Dates for RCC
Table 26: Key Historical and Projected Patent Expiry Dates for RCC
Table 27: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for RCC in 2018 and 2028
Figure 2: Analysis of the Company Portfolio Gap in RCC During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that the publisher Expects to be Licensed for the Treatment of RCC During the Forecast Period
Figure 4: Key pathways and drug targets in RCC.
Figure 5: 8MM, Diagnosed Incidence of RCC, Men, Ages ≥18 Years, 2008-2028
Figure 6: 8MM, Diagnosed Incidence of RCC, Women, Ages ≥18 Years, 2008-2028
Figure 7: 8MM, Sources Used, Diagnosed Incident Cases of RCC
Figure 8: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Stage at Diagnosis
Figure 9: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Prognostic Model
Figure 10: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Biomarker (Overexpression of EGFR)
Figure 11: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Biomarker (Overexpression of VEGF)
Figure 12: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Biomarker (Overexpression of mTOR)
Figure 13: 8MM, Sources Used, Five-Year and 10-Year Diagnosed Prevalent Cases of RCC
Figure 14: 8MM, Diagnosed Incident Cases of RCC, Ages ≥18 Years, Both Sexes, N, 2018
Figure 15: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N, 2018
Figure 16: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ≥18 Years, N, 2018
Figure 17: 8MM, Diagnosed Incident Cases of RCC by Stage at Diagnosis, Ages ≥18 Years, Both Sexes, N, 2018
Figure 18: 8MM, Diagnosed Incident Cases of RCC Stage IV by Prognostic Model, Ages ≥18 Years, Both Sexes, N, 2018
Figure 19: 8MM, Diagnosed Incident Cases of RCC Stage IV by Biomarkers, Ages ≥18 Years, Both Sexes, N, 2018
Figure 20: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥18 Years, Both Sexes, N, 2018
Figure 21: 8MM, 10-Year Diagnosed Prevalent Cases of RCC, Ages ≥18 Years, Both Sexes, N, 2018
Figure 22: Treatment Algorithm for advanced/metastatic RCC
Figure 23: Unmet Needs and Opportunities in RCC
Figure 24: Overview of the Development Pipeline in RCC, 2019
Figure 25: Pivotal Phase II/III Trials for the Promising RCC Pipeline Agents, 2019
Figure 26: Competitive Assessment of the Late-Stage Pipeline Agents for RCC, 2018-2028
Figure 27: Analysis of the Company Portfolio Gap in RCC During the Forecast Period
Figure 28: Global (8MM) Sales Forecast by Country for RCC in 2018 and 2028
Figure 29: Sales Forecast by Class for RCC in the US in 2018 and 2028
Figure 30: Sales Forecast by Class for RCC in the 5EU in 2018 and 2028
Figure 31: Sales Forecast by Class for RCC in Japan in 2018 and 2028
Figure 32: Sales Forecast by Class for RCC in China in 2018 and 2028
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Altor Biosciences
- Aveo Pharma
- Bayer
- Calithera Biosciences
- Xynomic Pharmaceuticals
- Eisai
- Merck kGaA
- AstraZeneca
- Betta Pharmaceuticals
- Bristol-Myers-Squibb
- Exelixis
- Merck & Co.
- Nektar Therapeutics
- Novartis
- Pfize
